Last updated: October 25, 2026
Qtern is AstraZeneca’s fixed-dose combination of dapagliflozin and saxagliptin for adults with type 2 diabetes. Its commercial position has weakened as the market shifted toward dapagliflozin monotherapy, GLP-1 therapies, and newer combination regimens. Qtern remains commercially differentiated by combining an SGLT2 inhibitor with a DPP-4 inhibitor, but it lacks the growth profile and cardiovascular market access of Farxiga. AstraZeneca does not separately disclose material global Qtern revenue in its recent annual reporting, which limits product-level financial modeling.[1]
What is Qtern and how does it compete in type 2 diabetes?
Qtern combines two oral antihyperglycemic agents:
| Product |
Active ingredients |
Drug classes |
Manufacturer |
FDA approval |
| Qtern |
Dapagliflozin 10 mg/saxagliptin 5 mg |
SGLT2 inhibitor/DPP-4 inhibitor |
AstraZeneca |
2017 |
| Farxiga |
Dapagliflozin |
SGLT2 inhibitor |
AstraZeneca |
2014 |
| Onglyza |
Saxagliptin |
DPP-4 inhibitor |
AstraZeneca |
2009 |
| Glyxambi |
Empagliflozin/linagliptin |
SGLT2 inhibitor/DPP-4 inhibitor |
Boehringer Ingelheim/Eli Lilly |
2015 |
| Trijardy XR |
Empagliflozin/linagliptin/metformin |
SGLT2 inhibitor/DPP-4 inhibitor/metformin |
Boehringer Ingelheim/Eli Lilly |
2020 |
Qtern is administered once daily and is intended for patients who require additional glycemic control despite treatment with dapagliflozin or saxagliptin, or who are transitioning from the two individual products. The product does not contain metformin, which narrows its addressable population because metformin remains a common foundation therapy.[2]
The commercial rationale was to increase adherence and defend the combined use of two AstraZeneca diabetes products. That strategy was weakened by the rapid expansion of Farxiga’s indications in heart failure and chronic kidney disease. Those indications increased the value of dapagliflozin as a single-agent franchise while reducing the need to use Qtern as a primary growth vehicle.
What FDA regulatory status does Qtern have?
Qtern was approved by the FDA on September 27, 2017, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[2] It was not approved for type 1 diabetes, diabetic ketoacidosis, weight reduction, heart failure, or chronic kidney disease.
FDA label and safety profile
The Qtern label carries warnings associated with both components:
- Ketoacidosis and volume depletion risks from dapagliflozin.
- Genitourinary infections and rare serious infections associated with SGLT2 inhibition.
- Pancreatitis and heart-failure concerns associated with saxagliptin.
- Hypoglycemia risk when used with insulin or insulin secretagogues.
- Renal function limitations and dose considerations.
Qtern’s clinical value is therefore narrower than Farxiga’s. Farxiga has FDA indications for reducing the risk of hospitalization for heart failure in adults with heart failure and for reducing the risk of sustained kidney-function decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in selected chronic kidney disease patients.[3]
When does Qtern lose exclusivity?
Qtern’s regulatory and patent exclusivity should be analyzed separately.
| Exclusivity category |
Relevant date or status |
Commercial implication |
| FDA approval |
September 27, 2017 |
Established the U.S. product franchise |
| New chemical entity exclusivity |
Not applicable to Qtern as a fixed-dose combination of previously approved ingredients |
No five-year NCE period |
| Clinical-investigation exclusivity |
Potential three-year period associated with approval-supporting studies |
Protected the approved application from certain abbreviated applications during the applicable period |
| Combination-product patent |
U.S. Orange Book-listed patent protection has been associated with Qtern |
Can delay or complicate direct generic substitution |
| Dapagliflozin compound patents |
Core U.S. protection largely expired before or around the early 2020s, subject to patent-specific extensions and litigation |
Does not by itself determine Qtern entry |
| Saxagliptin compound patents |
Earlier than Qtern’s combination protection |
The active ingredient alone is not the principal long-term barrier |
| Pediatric exclusivity |
Must be verified against the applicable FDA listing and patent records |
Could add six months to qualifying protection |
The key protection is the combination-product estate rather than the underlying active ingredients. A generic manufacturer may be able to challenge Qtern’s listed combination patent even after the individual dapagliflozin and saxagliptin patents have expired.
Public patent databases and FDA Orange Book records should be read together because patent expiration dates can differ based on patent-term adjustment, patent-term extension, pediatric exclusivity, terminal disclaimers, and listing corrections.[4]
What patents protect Qtern?
Qtern’s patent protection is centered on fixed-dose combinations containing dapagliflozin and saxagliptin. U.S. patent records have associated the product with AstraZeneca entities and combination claims covering pharmaceutical compositions and methods of treating diabetes.
A commonly cited Qtern patent is U.S. Patent No. 9,669,097, with an expiration date reported in public patent databases in the early 2030s, subject to statutory adjustments and regulatory extensions. The patent’s relevance is greater than the earlier compound patents because it targets the co-formulated product rather than one active ingredient alone.[5]
Patent protection by layer
| Patent layer |
Protected subject matter |
Strength for Qtern |
| Dapagliflozin compound patents |
SGLT2 inhibitor active ingredient |
Limited as a standalone barrier after expiration |
| Saxagliptin compound patents |
DPP-4 inhibitor active ingredient |
Limited as a standalone barrier after expiration |
| Fixed-dose combination patents |
Dapagliflozin plus saxagliptin compositions |
Core Qtern protection |
| Formulation patents |
Tablet composition, excipients, release and stability characteristics |
May complicate design-around strategies |
| Method-of-use patents |
Use of the combination in type 2 diabetes |
Relevant where listed and enforceable |
| Manufacturing patents |
Processes for producing active ingredients or dosage forms |
More important for supply-chain control than automatic product blocking |
The practical strength of the estate depends on claim scope, prosecution history, validity challenges, and whether a generic applicant can formulate a non-infringing version. A patent directed narrowly to a specific ratio, excipient system, or formulation process may be easier to design around than a broad composition claim.
What is the Orange Book status of Qtern?
Qtern is an FDA-approved prescription drug whose patent listings must be assessed through the FDA’s Orange Book and related regulatory records. The Orange Book identifies patents that the NDA holder submits for the approved drug, but listing does not establish patent validity or infringement.[4]
A generic applicant seeking approval through an ANDA may make a Paragraph IV certification alleging that a listed patent is invalid, unenforceable, or will not be infringed. If the NDA holder brings suit within the statutory period, FDA approval of the ANDA can be subject to a 30-month stay, subject to court decisions and statutory exceptions.
No reliable public evidence establishes a commercially significant Qtern Paragraph IV launch challenge or a final judgment eliminating its principal listed combination patent. The absence of a public challenge does not prove that no certification has been filed, because litigation records, settlement terms, and regulatory correspondence may not fully disclose the commercial status of every filing.
Which companies are challenging Qtern?
The public record does not identify a major generic launch against Qtern comparable to the challenges directed at high-revenue products such as Farxiga, Januvia, or major oncology therapies.
Potential challengers include generic companies with diabetes portfolios and manufacturing capabilities in oral solid-dose products. The most likely entry route would be an ANDA supported by a Paragraph IV certification against the principal Qtern combination patent. A generic company could also pursue a different formulation or seek approval after listed patent expiry through Paragraph III certifications.
The economic incentive to challenge Qtern is lower than the incentive to challenge Farxiga. Qtern revenue is not separately reported as a major AstraZeneca product, while Farxiga generates multi-billion-dollar annual sales. Generic companies typically prioritize products with larger reimbursed markets, stronger pharmacy substitution potential, and less complex combination-product risk.
What formulation patents protect Qtern?
Qtern’s commercial product is a film-coated immediate-release tablet containing dapagliflozin and saxagliptin. Formulation protection may cover:
- The co-presence of both active ingredients in one dosage form.
- Specific active-ingredient ratios.
- Excipients and tablet architecture.
- Dissolution and stability characteristics.
- Manufacturing conditions that preserve the performance of both compounds.
Formulation patents can create a secondary barrier after active-ingredient patents expire. Their value depends on whether the claims cover the clinically relevant product broadly or only a narrow manufacturing implementation.
A generic applicant may avoid infringement by using different excipients, compression conditions, coating systems, or particle characteristics, provided the resulting product satisfies FDA bioequivalence requirements. Qtern therefore has a more complex generic pathway than a conventional single-ingredient tablet, but it does not necessarily have an insurmountable barrier.
How has Qtern’s financial trajectory developed?
AstraZeneca has concentrated financial disclosure on the broader diabetes portfolio rather than Qtern as a standalone product. Farxiga is the company’s principal diabetes growth asset and has expanded through cardiovascular, renal, and heart-failure indications. Qtern has not been identified as a comparable growth driver in the company’s reported product portfolio.[1]
Financial trajectory
| Period |
Market position |
Financial interpretation |
| 2017-2019 |
New fixed-dose combination |
Initial uptake depended on patients already using or eligible for both components |
| 2020-2021 |
Broader SGLT2 adoption |
Qtern competed with growing preference for SGLT2 monotherapy and other combinations |
| 2022-2024 |
Farxiga expansion in heart failure and CKD |
Value shifted toward dapagliflozin’s outcome-based indications |
| Longer term |
Patent and generic pressure |
Combination-product protection may delay entry, but market growth is unlikely to match Farxiga |
Qtern’s revenue exposure is likely modest relative to AstraZeneca’s total diabetes franchise. Because AstraZeneca does not consistently disclose Qtern sales as a separate material line item, analysts should avoid treating total Farxiga or total diabetes revenue as Qtern revenue.
A practical model should use Qtern as a declining or stable specialty product rather than a major revenue-growth asset. Key variables are:
- Net price after rebates and payer discounts.
- Whether payers prefer separate Farxiga and saxagliptin prescriptions.
- Generic availability of either component.
- Qtern’s formulary tier relative to Glyxambi and Trijardy XR.
- Physician preference for therapies with demonstrated cardiovascular and renal outcomes.
- Any future generic entry against the fixed-dose combination.
How does Qtern compare with Farxiga and Glyxambi?
| Factor |
Qtern |
Farxiga |
Glyxambi |
| Components |
Dapagliflozin/saxagliptin |
Dapagliflozin |
Empagliflozin/linagliptin |
| Primary value proposition |
Dual oral glycemic control |
Glycemic, heart-failure and renal outcomes |
Dual oral glycemic control |
| Cardiovascular and renal label breadth |
Narrower |
Broader |
More limited relative to Farxiga |
| Manufacturer |
AstraZeneca |
AstraZeneca |
Boehringer Ingelheim/Eli Lilly |
| Main commercial risk |
Low growth and generic combination entry |
Future SGLT2 competition and patent loss |
Competition from Jardiance and fixed-dose combinations |
| Strategic role |
Franchise defense and adherence product |
Major growth and outcomes franchise |
Combination competitor |
Qtern’s principal disadvantage is that its combination benefit is primarily glycemic, while Farxiga’s market expansion is tied to outcomes that extend beyond glucose lowering. Payers and clinicians have increasingly prioritized therapies with evidence in heart failure and chronic kidney disease.
What licensing deals affect Qtern?
AstraZeneca commercializes Qtern within its own dapagliflozin and saxagliptin diabetes franchise. No major separate Qtern-specific licensing transaction has been publicly identified as a central driver of the product’s commercial position.
The broader dapagliflozin franchise has been subject to collaboration and regional commercialization arrangements, particularly in relation to diabetes and cardiovascular products. Those arrangements should not be treated as Qtern-specific revenue-sharing agreements unless the contract expressly identifies Qtern.
What generic launch scenarios exist for Qtern?
Scenario 1: Delayed fixed-dose generic entry
A generic applicant challenges the combination patent, but litigation preserves market exclusivity until patent expiry or settlement. Qtern maintains branded pricing but faces declining utilization as physicians prescribe the individual components.
Scenario 2: At-risk launch
A generic manufacturer launches before final resolution after receiving a favorable litigation position. AstraZeneca could seek damages, an injunction, or other remedies. This scenario would create rapid price erosion if pharmacy substitution occurs.
Scenario 3: Separate-component substitution
Generic dapagliflozin and saxagliptin become available without a direct Qtern generic. Physicians and payers substitute the two individual products, reducing Qtern demand while avoiding direct infringement of a fixed-dose combination patent.
Scenario 4: Authorized generic or settlement entry
AstraZeneca could permit an authorized generic or settle with a challenger under terms that specify an entry date, license restrictions, or supply arrangements. No major public Qtern settlement has been established as the defining market event.
How strong is the Qtern patent estate?
Qtern’s patent estate is moderate rather than dominant.
Its strengths are:
- A fixed-dose combination provides a distinct product claim relative to single-agent patents.
- The product has two established active ingredients and a defined tablet formulation.
- Generic developers must satisfy combination-product bioequivalence requirements.
Its weaknesses are:
- The active ingredients are mature and widely understood.
- The medical market increasingly favors broader outcome indications associated with dapagliflozin.
- Generic manufacturers may design around narrow formulation claims.
- Qtern’s relatively modest revenue reduces litigation incentives for both sides.
- Separate generic components can erode demand without a direct Qtern copy.
Patent strength should therefore be measured by the ability to preserve Qtern’s net price and volume, not only by the nominal expiration date of a listed patent.
What patent litigation affects Qtern?
No major public litigation outcome has been identified as changing Qtern’s U.S. commercial status. The relevant litigation risk remains a potential Paragraph IV challenge to the listed fixed-dose combination patent.
A complete litigation review should distinguish:
- ANDA patent litigation under the Hatch-Waxman Act.
- Declaratory-judgment actions.
- Patent-office post-grant proceedings.
- Settlement agreements.
- Foreign opposition and revocation proceedings.
- Litigation involving Farxiga or Onglyza that does not directly affect Qtern.
Foreign patent outcomes may differ from U.S. outcomes because national courts assess validity and infringement independently. European, Canadian, Japanese, and other market positions should not be inferred from the U.S. Orange Book.
What geographic coverage does Qtern have?
Qtern has been marketed in multiple jurisdictions under AstraZeneca’s diabetes portfolio, but approval, reimbursement, patent coverage, and commercial availability vary by country. In some markets, the product may be known under a different brand or may face different regulatory treatment.
Geographic risk is highest where:
- Combination patents have expired or were never granted.
- Generic substitution is strong.
- Payers favor separate low-cost components.
- SGLT2 outcomes products receive preferential reimbursement.
- Local manufacturing or compulsory-license rules affect supply.
The United States remains the most important patent and litigation jurisdiction because of Hatch-Waxman procedures, Orange Book listings, and the potential for Paragraph IV-driven market entry.
Key Takeaways
- Qtern combines dapagliflozin and saxagliptin in a once-daily fixed-dose tablet.
- AstraZeneca’s commercial strategy has shifted toward Farxiga’s heart-failure and chronic-kidney-disease indications.
- Qtern is not a major separately reported revenue driver in AstraZeneca’s recent disclosures.
- The core Qtern protection is the fixed-dose combination and formulation patent estate, not the older individual compound patents.
- A commonly cited Qtern patent is U.S. Patent No. 9,669,097, with reported expiration in the early 2030s, subject to patent-term adjustments and regulatory extensions.
- No major public Paragraph IV challenge or settlement has been established as the defining Qtern market event.
- Generic erosion may occur through separate dapagliflozin and saxagliptin products even without a direct Qtern generic.
- Qtern’s patent estate is moderate: it can delay direct combination entry but does not provide the commercial leverage of Farxiga’s broader outcomes franchise.
FAQs About Qtern Patents, Sales, and Generic Entry
Is Qtern the same as Farxiga?
No. Qtern contains dapagliflozin plus saxagliptin. Farxiga contains dapagliflozin alone and has broader FDA indications for heart failure and chronic kidney disease.
Does Qtern have new chemical entity exclusivity?
No. Qtern combines previously approved active ingredients and therefore does not receive a five-year NCE exclusivity period for a new active moiety.
Can generic companies substitute separate dapagliflozin and saxagliptin for Qtern?
Yes, subject to prescribing, payer, and substitution rules. Separate products may reduce Qtern demand even if no generic obtains approval for the Qtern fixed-dose tablet.
Does Qtern have an FDA pediatric extension?
The applicable FDA Orange Book and regulatory records must be reviewed for any pediatric exclusivity attached to a listed Qtern patent. A pediatric extension, if granted, can add six months to qualifying patent protection.
Is Qtern still commercially important to AstraZeneca?
Qtern remains part of AstraZeneca’s diabetes portfolio, but its strategic and financial importance is materially lower than Farxiga’s. AstraZeneca’s public reporting does not identify Qtern as a comparable standalone growth product.
References
- AstraZeneca. (2024). Annual report and Form 20-F 2023. AstraZeneca PLC.
- U.S. Food and Drug Administration. (2017). Qtern (dapagliflozin and saxagliptin) prescribing information.
- U.S. Food and Drug Administration. (2023). Farxiga (dapagliflozin) prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,669,097: Dapagliflozin and saxagliptin pharmaceutical compositions.